董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joseph Tenne | 男 | Director | 61 | 未披露 | 未持股 | 2017-03-10 |
| Holger Liepmann | 男 | Director | 65 | 未披露 | 未持股 | 2017-03-10 |
| Tamar Howson | 女 | Director | 68 | 未披露 | 未持股 | 2017-03-10 |
| Steve Dubin | 男 | Chairman of the Board | 63 | 53.20万美元 | 未持股 | 2017-03-10 |
| Nir Belzer | 男 | Director | 54 | 未披露 | 未持股 | 2017-03-10 |
| Dov Pekelman | 男 | Director | 76 | 未披露 | 未持股 | 2017-03-10 |
| Yossi Peled | 男 | Director | 69 | 未披露 | 未持股 | 2017-03-10 |
| Imanuel Wasserman | 男 | Director | 50 | 未披露 | 未持股 | 2017-03-10 |
| Michal Silverberg | 女 | Director | 40 | 未披露 | 未持股 | 2017-03-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert Crim | 男 | President and CEO VAYA Pharma USA | 59 | 39.80万美元 | 未持股 | 2017-03-10 |
| Itay Dromi | 男 | Vice President - Human Resources and Information Systems | 52 | 未披露 | 未持股 | 2017-03-10 |
| Yael Richter | 女 | Vice President - Research and Development | 42 | 未披露 | 未持股 | 2017-03-10 |
| Avner Avissara | 男 | Vice President - Nutrition Division | 51 | 未披露 | 未持股 | 2017-03-10 |
| Efrat Manoff | 女 | Vice President - Operations | 38 | 未披露 | 未持股 | 2017-03-10 |
| Ariel Katz | 男 | President and Chief Executive Officer | 58 | 51.00万美元 | 未持股 | 2017-03-10 |
| Oren Bryan | 男 | Vice President and Chief Financial Officer | 42 | 30.90万美元 | 未持股 | 2017-03-10 |
| Gai Ben Dror | 男 | Vice President - Process Development | 48 | 25.90万美元 | 未持股 | 2017-03-10 |
董事简历
中英对照 | 中文 | 英文- Joseph Tenne
-
Joseph Tenne，自2014年8月起担任MIND CTI LTD的独立董事。自2017年5月起，他担任Itamar Medical Ltd.的财务顾问。纳斯达克和TASE:ITMR。他担任AudioCodes Ltd.、OPC Energy Ltd.、Sapir Corp Ltd.和Ratio Oil Explorations (Finance) Ltd.的董事。从2014年到2017年，Tenne先生担任Itamar Medical Ltd.的首席财务官和财务副总裁。从2005年到2013年，他担任Ormat Technologies, Inc. (NYSE和TASE: ORA)的首席财务官。从1997年到2003年，Tenne先生是Kesselman & Kesselman的合伙人，PricewaterhouseCoopers International Limited (PwC Israel)的成员。他持有Tel Aviv University的会计和经济学学士学位以及工商管理硕士学位。他也是以色列的注册会计师。
Joseph Tenne has served as an independent director of MIND CTI LTD since August 2014. Since May 2017 Mr. Tenne served as a financial consultant to Itamar Medical Ltd. NASDAQ and TASE: ITMR. Mr. Tenne serves as a director at AudioCodes Ltd., at OPC Energy Ltd., at Sapir Corp Ltd. and at Ratio Oil Explorations (Finance) Ltd. From 2014 to 2017 Mr. Tenne served as the CFO and VP Finance of Itamar Medical Ltd. From 2005 to 2013 Mr. Tenne served as the CFO of Ormat Technologies, Inc. (NYSE and TASE: ORA). From 1997 until 2003 Mr. Tenne was a partner in Kesselman & Kesselman, a member of PricewaterhouseCoopers International Limited ("PwC Israel"). Mr. Tenne holds a B.A. degree in Accounting and Economics and an M.B.A. degree from Tel Aviv University. Mr. Tenne is also a Certified Public Accountant in Israel. - Joseph Tenne，自2014年8月起担任MIND CTI LTD的独立董事。自2017年5月起，他担任Itamar Medical Ltd.的财务顾问。纳斯达克和TASE:ITMR。他担任AudioCodes Ltd.、OPC Energy Ltd.、Sapir Corp Ltd.和Ratio Oil Explorations (Finance) Ltd.的董事。从2014年到2017年，Tenne先生担任Itamar Medical Ltd.的首席财务官和财务副总裁。从2005年到2013年，他担任Ormat Technologies, Inc. (NYSE和TASE: ORA)的首席财务官。从1997年到2003年，Tenne先生是Kesselman & Kesselman的合伙人，PricewaterhouseCoopers International Limited (PwC Israel)的成员。他持有Tel Aviv University的会计和经济学学士学位以及工商管理硕士学位。他也是以色列的注册会计师。
- Joseph Tenne has served as an independent director of MIND CTI LTD since August 2014. Since May 2017 Mr. Tenne served as a financial consultant to Itamar Medical Ltd. NASDAQ and TASE: ITMR. Mr. Tenne serves as a director at AudioCodes Ltd., at OPC Energy Ltd., at Sapir Corp Ltd. and at Ratio Oil Explorations (Finance) Ltd. From 2014 to 2017 Mr. Tenne served as the CFO and VP Finance of Itamar Medical Ltd. From 2005 to 2013 Mr. Tenne served as the CFO of Ormat Technologies, Inc. (NYSE and TASE: ORA). From 1997 until 2003 Mr. Tenne was a partner in Kesselman & Kesselman, a member of PricewaterhouseCoopers International Limited ("PwC Israel"). Mr. Tenne holds a B.A. degree in Accounting and Economics and an M.B.A. degree from Tel Aviv University. Mr. Tenne is also a Certified Public Accountant in Israel.
- Holger Liepmann
-
Holger Liepmann自2015年2月起担任Enzymotec董事。从1986年到2011年退休，他在雅培公司担任过多个职位。2006年至2011年，Liepmann先生担任雅培公司营养产品执行Vice President。他负责雅培公司全球营养业务的各个方面，包括研发、制造、供应链和商业运营，并向雅培首席执行官汇报。此前，他曾担任制药产品集团、雅培国际公司（Abbott International）高级副总裁，、雅培国际制药业务的商业运营以及Vice President日本业务的执行Vice President。他在日本、西班牙、波多黎各、德国和美国任职，享有国际职业生涯。加入Abbott之前，Liepmann从1975年到1986年在Bayer AG担任多个职位，包括美国和德国。Liepmann先生在达特茅斯学院（Dartmouth College）获得学士学位，在斯坦福大学（Stanford University）获得工商管理硕士学位。他目前任职Altan Pharma Ltd.（他共同创立的公司）、Desert Research Institute Foundation和Smarttots（两个非政府组织）的董事会。
Holger Liepmann has served as a director of Enzymotec since February 2015. He served in various positions with Abbott Laboratories from 1986 until his retirement in 2011. From 2006 to 2011 Mr. Liepmann served as executive vice president, Nutritional Products of Abbott Laboratories. In this capacity he was responsible for all aspects of Abbott Laboratories’ global nutritional business, including R&D, manufacturing, supply chain and commercial operations, and reported to Abbott’s CEO. Previously, he served as executive vice president, Pharmaceutical Products Group, senior vice president, Abbott International, the commercial operations for Abbott's international pharmaceutical business, and vice president Japan Operations. He enjoyed an international career with postings in Japan, Spain, Puerto Rico, Germany and the United States. Prior to joining Abbott, Mr. Liepmann worked for Bayer AG in a variety of capacities between 1975 and 1986 both in the U.S. and in Germany. Mr. Liepmann earned a bachelor’s degree from Dartmouth College and a master’s degree in business administration from Stanford University. He currently sits on the boards of Altan Pharma Ltd., which he co-founded, and Desert Research Institute Foundation and SmartTots, two non-governmental organizations. - Holger Liepmann自2015年2月起担任Enzymotec董事。从1986年到2011年退休，他在雅培公司担任过多个职位。2006年至2011年，Liepmann先生担任雅培公司营养产品执行Vice President。他负责雅培公司全球营养业务的各个方面，包括研发、制造、供应链和商业运营，并向雅培首席执行官汇报。此前，他曾担任制药产品集团、雅培国际公司（Abbott International）高级副总裁，、雅培国际制药业务的商业运营以及Vice President日本业务的执行Vice President。他在日本、西班牙、波多黎各、德国和美国任职，享有国际职业生涯。加入Abbott之前，Liepmann从1975年到1986年在Bayer AG担任多个职位，包括美国和德国。Liepmann先生在达特茅斯学院（Dartmouth College）获得学士学位，在斯坦福大学（Stanford University）获得工商管理硕士学位。他目前任职Altan Pharma Ltd.（他共同创立的公司）、Desert Research Institute Foundation和Smarttots（两个非政府组织）的董事会。
- Holger Liepmann has served as a director of Enzymotec since February 2015. He served in various positions with Abbott Laboratories from 1986 until his retirement in 2011. From 2006 to 2011 Mr. Liepmann served as executive vice president, Nutritional Products of Abbott Laboratories. In this capacity he was responsible for all aspects of Abbott Laboratories’ global nutritional business, including R&D, manufacturing, supply chain and commercial operations, and reported to Abbott’s CEO. Previously, he served as executive vice president, Pharmaceutical Products Group, senior vice president, Abbott International, the commercial operations for Abbott's international pharmaceutical business, and vice president Japan Operations. He enjoyed an international career with postings in Japan, Spain, Puerto Rico, Germany and the United States. Prior to joining Abbott, Mr. Liepmann worked for Bayer AG in a variety of capacities between 1975 and 1986 both in the U.S. and in Germany. Mr. Liepmann earned a bachelor’s degree from Dartmouth College and a master’s degree in business administration from Stanford University. He currently sits on the boards of Altan Pharma Ltd., which he co-founded, and Desert Research Institute Foundation and SmartTots, two non-governmental organizations.
- Tamar Howson
-
Tamar Howson，她于2013年6月加入Organovo Holdings, Inc.的董事会，担任董事候选人。她担任生物制药公司的公司业务发展和战略顾问（自2011年以来）。从2009年到2011年，她担任JSB-Partners公司（事务咨询公司，为生命科学公司提供业务发展支持）的一员。从2007年到2008年，她担任 Lexicon Pharmaceuticals公司（生物科技公司）的执行副总裁，负责公司业务发展。加入Lexicon Pharmaceuticals公司之前，她曾担任Bristol-Myers Squibb公司的高级副总裁，负责公司和业务发展。她目前任职于Warner Chilcott Public Limited Company、 Idenix Pharmaceuticals Inc. 和OXiGENE公司。五年之前，她还担任BioLineRx公司、S*BIO Pte公司和Soligenix公司。此外，她也担任Microbicides公司（一个非盈利的产品开发合伙企业）的国际伙伴关系董事。她曾任职于Aradigm、Soligenix、S*BIO、Ariad Pharmaceuticals、SkyePharma、NPS Pharma、Targacept公司和HBA公司的董事会。她持有哥伦比亚大学（Columbia University）的工商管理硕士学位、纽约城市大学（City College of New York ）的硕士学位，以及以色列理工学院（the Technion， Israel）的化学工程学士学位。
Tamar Howson,has been a member of the Board since October 2019.Ms. Howson has served as an Independent Director at MEI Pharma, Inc. since September 2019, and Cue Biopharma, Inc since September 2020.She previously served as an Independent Director at Organovo Holdings, Inc. from June 2013 until September 2019, Enzymotec until December 2017, ContraVir until October 2018 and Scientus Pharma until December 2019.Tamar Howson joined Organovo Holdings, Inc. Board in June 2013. Ms. Howson has served as a corporate business development and strategy consultant to biopharmaceutical companies since 2011. From 2009 to 2011 she served as a member of the transaction advisory firm, JSB-Partners, providing business development support to life sciences companies. From 2007 to 2008 Ms. Howson served as Executive Vice President, Corporate Business Development at Lexicon Pharmaceuticals, a biotech company. Prior to joining Lexicon Pharmaceuticals, Ms. Howson served as Senior Vice President, Corporate and Business Development at Bristol-Myers Squibb. Ms. Howson currently serves on the board of directors of the following publicly traded companies: ContraVir Pharmaceuticals, Inc. and Enzymotec PLC. During the prior five years, Ms. Howson served as a director of the following publicly traded companies: OXiGENE, Inc., Cynapsus Therapeutics Inc., Actavis plc, Idenix Pharmaceuticals Inc., Warner Chilcott plc, Soligenix, Inc. and Cardax, Inc. In addition, Ms. Howson serves as a director of the International Partnership for Microbicides, a non-profit product development partnership. She previously served on the boards of Aradigm, S*BIO, Ariad Pharmaceuticals, SkyePharma, NPS Pharma, Targacept, and HBA. Ms. Howson holds an MBA from Columbia University, a MS from City University of New York, and a BS in Chemical Engineering from the Technion, Israel. - Tamar Howson，她于2013年6月加入Organovo Holdings, Inc.的董事会，担任董事候选人。她担任生物制药公司的公司业务发展和战略顾问（自2011年以来）。从2009年到2011年，她担任JSB-Partners公司（事务咨询公司，为生命科学公司提供业务发展支持）的一员。从2007年到2008年，她担任 Lexicon Pharmaceuticals公司（生物科技公司）的执行副总裁，负责公司业务发展。加入Lexicon Pharmaceuticals公司之前，她曾担任Bristol-Myers Squibb公司的高级副总裁，负责公司和业务发展。她目前任职于Warner Chilcott Public Limited Company、 Idenix Pharmaceuticals Inc. 和OXiGENE公司。五年之前，她还担任BioLineRx公司、S*BIO Pte公司和Soligenix公司。此外，她也担任Microbicides公司（一个非盈利的产品开发合伙企业）的国际伙伴关系董事。她曾任职于Aradigm、Soligenix、S*BIO、Ariad Pharmaceuticals、SkyePharma、NPS Pharma、Targacept公司和HBA公司的董事会。她持有哥伦比亚大学（Columbia University）的工商管理硕士学位、纽约城市大学（City College of New York ）的硕士学位，以及以色列理工学院（the Technion， Israel）的化学工程学士学位。
- Tamar Howson,has been a member of the Board since October 2019.Ms. Howson has served as an Independent Director at MEI Pharma, Inc. since September 2019, and Cue Biopharma, Inc since September 2020.She previously served as an Independent Director at Organovo Holdings, Inc. from June 2013 until September 2019, Enzymotec until December 2017, ContraVir until October 2018 and Scientus Pharma until December 2019.Tamar Howson joined Organovo Holdings, Inc. Board in June 2013. Ms. Howson has served as a corporate business development and strategy consultant to biopharmaceutical companies since 2011. From 2009 to 2011 she served as a member of the transaction advisory firm, JSB-Partners, providing business development support to life sciences companies. From 2007 to 2008 Ms. Howson served as Executive Vice President, Corporate Business Development at Lexicon Pharmaceuticals, a biotech company. Prior to joining Lexicon Pharmaceuticals, Ms. Howson served as Senior Vice President, Corporate and Business Development at Bristol-Myers Squibb. Ms. Howson currently serves on the board of directors of the following publicly traded companies: ContraVir Pharmaceuticals, Inc. and Enzymotec PLC. During the prior five years, Ms. Howson served as a director of the following publicly traded companies: OXiGENE, Inc., Cynapsus Therapeutics Inc., Actavis plc, Idenix Pharmaceuticals Inc., Warner Chilcott plc, Soligenix, Inc. and Cardax, Inc. In addition, Ms. Howson serves as a director of the International Partnership for Microbicides, a non-profit product development partnership. She previously served on the boards of Aradigm, S*BIO, Ariad Pharmaceuticals, SkyePharma, NPS Pharma, Targacept, and HBA. Ms. Howson holds an MBA from Columbia University, a MS from City University of New York, and a BS in Chemical Engineering from the Technion, Israel.
- Steve Dubin
-
Steve Dubin于2014年1月担任Enzymotec Ltd.公司董事会主席，之前是副主席，于2013年4月被任命为董事。2011年11月，他担任SDA Ventures LLC公司高管，该公司主要针对健康和保健产品公司，从事协助新兴公司和中间市场公司处理包括商业开发、兼并、客户关系、发展策略及公司财政等问题。在SDA Ventures公司工作前，他担任位于纽约、芝加哥旧金山的全球私募股权投资公司Paine & Partners, LLC的资深顾问，主要从事人类和动物食品保健产品行业发现投资机会进行投资。2006年直到2011年2月被Royal DSM N.V。公司收购，他担任Martek Biosciences Corporation公司CEO。之后于2011年2月至2011年10月担任DSM的营养油类产品分部总裁，并于2011年11月至2012年10月担任DSM公司保健产品高级顾问。在1992年加入Martek公司之后他担任多个职位，包括首席财务官、财务主管、秘书、法律总顾问和商业开发高级副总裁等，他于2003年至2006年期间是Martek公司总裁。2000年至2003年，他联合创立并联合管理马里兰州一家天使投资俱乐部（angel-investing club），并于2001年至2002年一段时间担任Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C。公司法律顾问。他目前担任多家私人持有公司董事会成员，包括在NeurExpand Brain Center LLC公司即之前的The Brain Center, LLC公司担任董事会副主席、在MyCell Technologies公司及其子公司Oceans Omega LLC, and Alcresta, Inc.里担任董事会成员。2011年至2012年，他是Scerene Healthcare, Inc.董事会成员。他在马里兰大学（University of Maryland）获得会计学学士学位，在乔治华盛顿大学国家法律中心（National Law Center at George Washington University）获得法学博士学位。他是注册会计师并是Maryland Bar的成员。
Steve Dubin has served as a member of our board of directors since the completion of the merger of resTORbio and Former Adicet in September 2020. Since November 2011 Mr. Dubin has been a Principal in SDA Ventures LLC, a firm focused on assisting emerging growth and middle-market companies, primarily in the health & wellness and nutritional products markets, on matters including corporate development, business acquisition, customer relations, growth strategies and corporate finance. In connection with SDA Ventures LLC, Mr. Dubin acts as a Senior Advisor to Paine Schwartz Partners, LLC, a global private equity investment firm located in New York, and San Mateo, for the purpose of identifying and executing investment opportunities in the global human and animal food and nutritional products industries. From 2006 until its acquisition by Royal DSM N.V. in February 2011 Mr. Dubin served as Chief Executive Officer and a member of the board of directors of Martek Biosciences Corporation. He later served as President of DSM’s Nutritional Lipids Division from February 2011 through October 2011 and as a Senior Advisor to DSM Nutritional Products from November 2011 through October 2012. After joining Martek in 1992 and serving in various management positions, including Chief Financial Officer, Treasurer, Secretary, General Counsel and Senior Vice President, Business Development, he served as President of Martek from 2003 to 2006. Mr. Dubin currently serves as a member of the board of directors of privately held companies Alcresta Therapeutics, Inc., The UCAN Company, Triton Algae Innovations, Ltd. and Phytolon LTD. From January 2014 to January 2018 Mr. Dubin served on the board of directors of Enzymotec Ltd. Mr. Dubin is a certified public accountant and a member of the Maryland Bar. He holds a bachelor’s degree in accounting from the University of Maryland and a J.D. from the National Law Center at George Washington University. - Steve Dubin于2014年1月担任Enzymotec Ltd.公司董事会主席，之前是副主席，于2013年4月被任命为董事。2011年11月，他担任SDA Ventures LLC公司高管，该公司主要针对健康和保健产品公司，从事协助新兴公司和中间市场公司处理包括商业开发、兼并、客户关系、发展策略及公司财政等问题。在SDA Ventures公司工作前，他担任位于纽约、芝加哥旧金山的全球私募股权投资公司Paine & Partners, LLC的资深顾问，主要从事人类和动物食品保健产品行业发现投资机会进行投资。2006年直到2011年2月被Royal DSM N.V。公司收购，他担任Martek Biosciences Corporation公司CEO。之后于2011年2月至2011年10月担任DSM的营养油类产品分部总裁，并于2011年11月至2012年10月担任DSM公司保健产品高级顾问。在1992年加入Martek公司之后他担任多个职位，包括首席财务官、财务主管、秘书、法律总顾问和商业开发高级副总裁等，他于2003年至2006年期间是Martek公司总裁。2000年至2003年，他联合创立并联合管理马里兰州一家天使投资俱乐部（angel-investing club），并于2001年至2002年一段时间担任Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C。公司法律顾问。他目前担任多家私人持有公司董事会成员，包括在NeurExpand Brain Center LLC公司即之前的The Brain Center, LLC公司担任董事会副主席、在MyCell Technologies公司及其子公司Oceans Omega LLC, and Alcresta, Inc.里担任董事会成员。2011年至2012年，他是Scerene Healthcare, Inc.董事会成员。他在马里兰大学（University of Maryland）获得会计学学士学位，在乔治华盛顿大学国家法律中心（National Law Center at George Washington University）获得法学博士学位。他是注册会计师并是Maryland Bar的成员。
- Steve Dubin has served as a member of our board of directors since the completion of the merger of resTORbio and Former Adicet in September 2020. Since November 2011 Mr. Dubin has been a Principal in SDA Ventures LLC, a firm focused on assisting emerging growth and middle-market companies, primarily in the health & wellness and nutritional products markets, on matters including corporate development, business acquisition, customer relations, growth strategies and corporate finance. In connection with SDA Ventures LLC, Mr. Dubin acts as a Senior Advisor to Paine Schwartz Partners, LLC, a global private equity investment firm located in New York, and San Mateo, for the purpose of identifying and executing investment opportunities in the global human and animal food and nutritional products industries. From 2006 until its acquisition by Royal DSM N.V. in February 2011 Mr. Dubin served as Chief Executive Officer and a member of the board of directors of Martek Biosciences Corporation. He later served as President of DSM’s Nutritional Lipids Division from February 2011 through October 2011 and as a Senior Advisor to DSM Nutritional Products from November 2011 through October 2012. After joining Martek in 1992 and serving in various management positions, including Chief Financial Officer, Treasurer, Secretary, General Counsel and Senior Vice President, Business Development, he served as President of Martek from 2003 to 2006. Mr. Dubin currently serves as a member of the board of directors of privately held companies Alcresta Therapeutics, Inc., The UCAN Company, Triton Algae Innovations, Ltd. and Phytolon LTD. From January 2014 to January 2018 Mr. Dubin served on the board of directors of Enzymotec Ltd. Mr. Dubin is a certified public accountant and a member of the Maryland Bar. He holds a bachelor’s degree in accounting from the University of Maryland and a J.D. from the National Law Center at George Washington University.
- Nir Belzer
-
Nir Belzer自2007年担任Enzymotec公司董事。他是Aquagro Fund L.P.公司联合创立者，该公司是以色列首家主要从事清洁技术的基金会，并自2007年担任该公司任事股东。另外，他是Millennium Materials Technologies funds基金会联合创立者，该基金会自1998年是我公司一大股东。他在风险投资管理方面有20年丰富经验，包括管理以色列IDB集团基金等。1995年至1997年，他就职于Israeli high tech industry, at Globes，担任市场营销经理，该公司是以色列金融报纸业领头羊。在Israel Aerospace Industries Ltd.公司担任Lavi项目航空电子技术工程师。他在特拉维斯大学（Tel Aviv University）获得数学与计算机科学、航空电子技术学士，MBA硕士。依据我公司公司首次公开发行前生效的章程，根据Millennium Materials Technologies任命规则，他担任我们公司董事。
Nir Belzer has served as a director of Enzymotec since January 2007. Mr. Belzer is a co-founder of Aquagro Fund L.P., one of Israel’s first funds to focus on clean technologies, and has served as its Managing Partner since 2007. In addition, he is a co-founder of the Millennium Materials Technologies funds, which was previously a major shareholder of ours, and has served as Managing Partner of Millennium Materials Technologies funds since 1998. Mr. Belzer has 20 years of extensive experience in venture capital management, including fund management in Israel’s IDB Group. From 1995 to 1997 Mr. Belzer worked in the Israeli high tech industry, at Globes, a leading Israeli financial newspaper, as a Marketing Manager, and at Israel Aerospace Industries Ltd., as an avionics engineer for the Lavi project. Mr. Belzer was appointed as a director pursuant to Millennium Materials Technologies’ appointment rights under our articles of association in effect prior to our initial public offering. He holds a bachelor’s degree in mathematics, computer science and avionics and an M.B.A. from Tel Aviv University. Mr. Belzer was re-elected as director in 2015. - Nir Belzer自2007年担任Enzymotec公司董事。他是Aquagro Fund L.P.公司联合创立者，该公司是以色列首家主要从事清洁技术的基金会，并自2007年担任该公司任事股东。另外，他是Millennium Materials Technologies funds基金会联合创立者，该基金会自1998年是我公司一大股东。他在风险投资管理方面有20年丰富经验，包括管理以色列IDB集团基金等。1995年至1997年，他就职于Israeli high tech industry, at Globes，担任市场营销经理，该公司是以色列金融报纸业领头羊。在Israel Aerospace Industries Ltd.公司担任Lavi项目航空电子技术工程师。他在特拉维斯大学（Tel Aviv University）获得数学与计算机科学、航空电子技术学士，MBA硕士。依据我公司公司首次公开发行前生效的章程，根据Millennium Materials Technologies任命规则，他担任我们公司董事。
- Nir Belzer has served as a director of Enzymotec since January 2007. Mr. Belzer is a co-founder of Aquagro Fund L.P., one of Israel’s first funds to focus on clean technologies, and has served as its Managing Partner since 2007. In addition, he is a co-founder of the Millennium Materials Technologies funds, which was previously a major shareholder of ours, and has served as Managing Partner of Millennium Materials Technologies funds since 1998. Mr. Belzer has 20 years of extensive experience in venture capital management, including fund management in Israel’s IDB Group. From 1995 to 1997 Mr. Belzer worked in the Israeli high tech industry, at Globes, a leading Israeli financial newspaper, as a Marketing Manager, and at Israel Aerospace Industries Ltd., as an avionics engineer for the Lavi project. Mr. Belzer was appointed as a director pursuant to Millennium Materials Technologies’ appointment rights under our articles of association in effect prior to our initial public offering. He holds a bachelor’s degree in mathematics, computer science and avionics and an M.B.A. from Tel Aviv University. Mr. Belzer was re-elected as director in 2015.
- Dov Pekelman
-
Dov Pekelman自2010年10月担任Enzymotec公司董事。此外，Pekelman教授目前担任Taro Pharmaceuticals Industries Ltd. NYSE： TARO公司董事会特殊委员会主席，以及Atera Networks Ltd.，公司主席、Gilon Investments （TASE： GILN）公司主席、Makhteshim Agan Industries Ltd. （TASE： MAIN）公司董事。他是以色列赫兹利亚市Interdisciplinary Center （IDC）的Arison商学院的讲师，并担任IDC的董事会成员，是IDC公司中心经济部门主席。1985年至2008年，Pekelman教授担任Teva Pharmaceutical Industries Ltd. （NASDAQ： TEVA）公司高级顾问，并还创建并担任以色列的管理咨询公司P.O.C. Ltd.的领导人。在此之前，他担任多家大型工业公司包括Koor Industries Ltd. （TASE： KOR）的董事会成员，并是Bank of Israel咨询委员会成员。他在芝加哥大学（University of Chicago）获得博士学位，并在以色列海法市以色列理工大学（Technion - Israel Institute of Technology, Haifa, Israel）获得学士学位。
Dov Pekelman became a member of the Taro Board and Audit Committee in August 2011 Chairman of the Special Committee in November 2011 disbanded in February 2013 the Stock Option Committee in March 2012 (disbanded in January 2015) and the Compensation Committee in February 2013. Professor Pekelman is currently a major shareholder of Atera Networks Ltd. and a board member of Mapi Pharma, Ltd. He serves as Dean of the Business School at the Interdisciplinary Center (IDC), Herzliya, Israel, and is Chairman of the IDC Corporation, the center’s economic arm. Professor Pekelman served as a senior consultant to Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) from 1985 to 2008 and also founded and ran a leading, Israeli-based management-consulting firm, P.O.C. Ltd. Professor Pekelman served on the Board of Directors of several large industrial corporations, including Enzymotec (NASDAQ:ENZY), Koor Industries Ltd. (TASE: KOR) and served for 22 years on the Board of Directors of Makhteshim Agan Industries Ltd. (TASE: MAIN). Professor Pekelman was also a member of the advisory committee of the Bank of Israel. He holds a Ph.D. from the University of Chicago and a B.S. from the Technion, Israeli Institute of Technology. Professor Pekelman is a published author writing on various aspects of business operations. - Dov Pekelman自2010年10月担任Enzymotec公司董事。此外，Pekelman教授目前担任Taro Pharmaceuticals Industries Ltd. NYSE： TARO公司董事会特殊委员会主席，以及Atera Networks Ltd.，公司主席、Gilon Investments （TASE： GILN）公司主席、Makhteshim Agan Industries Ltd. （TASE： MAIN）公司董事。他是以色列赫兹利亚市Interdisciplinary Center （IDC）的Arison商学院的讲师，并担任IDC的董事会成员，是IDC公司中心经济部门主席。1985年至2008年，Pekelman教授担任Teva Pharmaceutical Industries Ltd. （NASDAQ： TEVA）公司高级顾问，并还创建并担任以色列的管理咨询公司P.O.C. Ltd.的领导人。在此之前，他担任多家大型工业公司包括Koor Industries Ltd. （TASE： KOR）的董事会成员，并是Bank of Israel咨询委员会成员。他在芝加哥大学（University of Chicago）获得博士学位，并在以色列海法市以色列理工大学（Technion - Israel Institute of Technology, Haifa, Israel）获得学士学位。
- Dov Pekelman became a member of the Taro Board and Audit Committee in August 2011 Chairman of the Special Committee in November 2011 disbanded in February 2013 the Stock Option Committee in March 2012 (disbanded in January 2015) and the Compensation Committee in February 2013. Professor Pekelman is currently a major shareholder of Atera Networks Ltd. and a board member of Mapi Pharma, Ltd. He serves as Dean of the Business School at the Interdisciplinary Center (IDC), Herzliya, Israel, and is Chairman of the IDC Corporation, the center’s economic arm. Professor Pekelman served as a senior consultant to Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) from 1985 to 2008 and also founded and ran a leading, Israeli-based management-consulting firm, P.O.C. Ltd. Professor Pekelman served on the Board of Directors of several large industrial corporations, including Enzymotec (NASDAQ:ENZY), Koor Industries Ltd. (TASE: KOR) and served for 22 years on the Board of Directors of Makhteshim Agan Industries Ltd. (TASE: MAIN). Professor Pekelman was also a member of the advisory committee of the Bank of Israel. He holds a Ph.D. from the University of Chicago and a B.S. from the Technion, Israeli Institute of Technology. Professor Pekelman is a published author writing on various aspects of business operations.
- Yossi Peled
-
Yossi Peled，自2001年6月担任Enzymotec公司董事，2009年6月至2011年10月，他担任Enzymotec Ltd.公司董事会主席。此外，他于1987年及1977年直至1984年担任Galam Ltd.公司CEO。他是Galam集团所属多个公司的董事会成员，包括Eurosweet GmbH公司（在其中担任董事会主席）及Galam Invest Ltd.公司。2001年至2003年，他担任以色列消防设备制造商主导企业Lehavot Fire Protection Ltd.公司的董事会主席。之前，他在Kibbutz Maanit和HaKibbutz HaArtzi中担任多个职位，HaKibbutz HaArtzi是以色列国有机构，是以色列250多家集体农场（kibbutzim）代表。他在以色列Ruppin Academic Center学习工商管理，并是特拉维斯大学工商管理系（the Faculty of Management Tel Aviv University）Lahav的高级商务管理人。依据我公司公司首次公开发行前生效的章程，根据Galam任命规则，他担任我们公司董事。
Yossi Peled has served as a director of Enzymotec since June 2001. From June 2009 to October 2011 Mr. Peled was the Chairman of our board of directors. In addition, he has served as the Chief Executive Officer of Galam Ltd. since 1987 and from 1977 until 1984. Mr. Peled is a member of the board of directors of a number of companies within the Galam Group, including Eurosweet GmbH of which he is Chairman and Galam Invest Ltd. From 2001 to 2003 Mr. Peled served as the Chairman of the board of directors of Lehavot Fire Protection Ltd., Israel’s leading fire protection equipment manufacturer. Previously, he held various managerial roles in Kibbutz Maanit and HaKibbutz HaArtzi, the national kibbutz organization in Israel, which represents more than 250 kibbutzim. Mr. Peled studied business administration at the Ruppin Academic Center, Israel, and executive business management at “Lahav” of the Faculty of Management Tel Aviv University. - Yossi Peled，自2001年6月担任Enzymotec公司董事，2009年6月至2011年10月，他担任Enzymotec Ltd.公司董事会主席。此外，他于1987年及1977年直至1984年担任Galam Ltd.公司CEO。他是Galam集团所属多个公司的董事会成员，包括Eurosweet GmbH公司（在其中担任董事会主席）及Galam Invest Ltd.公司。2001年至2003年，他担任以色列消防设备制造商主导企业Lehavot Fire Protection Ltd.公司的董事会主席。之前，他在Kibbutz Maanit和HaKibbutz HaArtzi中担任多个职位，HaKibbutz HaArtzi是以色列国有机构，是以色列250多家集体农场（kibbutzim）代表。他在以色列Ruppin Academic Center学习工商管理，并是特拉维斯大学工商管理系（the Faculty of Management Tel Aviv University）Lahav的高级商务管理人。依据我公司公司首次公开发行前生效的章程，根据Galam任命规则，他担任我们公司董事。
- Yossi Peled has served as a director of Enzymotec since June 2001. From June 2009 to October 2011 Mr. Peled was the Chairman of our board of directors. In addition, he has served as the Chief Executive Officer of Galam Ltd. since 1987 and from 1977 until 1984. Mr. Peled is a member of the board of directors of a number of companies within the Galam Group, including Eurosweet GmbH of which he is Chairman and Galam Invest Ltd. From 2001 to 2003 Mr. Peled served as the Chairman of the board of directors of Lehavot Fire Protection Ltd., Israel’s leading fire protection equipment manufacturer. Previously, he held various managerial roles in Kibbutz Maanit and HaKibbutz HaArtzi, the national kibbutz organization in Israel, which represents more than 250 kibbutzim. Mr. Peled studied business administration at the Ruppin Academic Center, Israel, and executive business management at “Lahav” of the Faculty of Management Tel Aviv University.
- Imanuel Wasserman
-
Imanuel Wasserman，自2011年担任Enzymotec董事。Wasserman博士是Beresheit General Partner Ltd.公司的联合创立者，是一家以色列网络信息服务20亿基金会（NIS 2 billion Israeli fund）Manof I funds的普通合伙人，并自该公司2009年起担任任事股东。他是三个由以色列政府最初建立的最大的Manof基金之一，通过提供债务、中间商及股权融资为以色列经济提供流动资产。以色列政府决心将5亿投资到NIS，由以色列的主导金融机构投资剩余的1.5亿。之前于2000年至2009年他是以色列战略和M&A咨询公司Magna Capital Ltd.的联合创立者和董事总经理。另外，他作为律师，于1992年至1994年至1997年至1999年就职于Zellermayer Pelossof and Co.，该公司是一家以色列律师事务所。1995年至1996年，他是美国一家律师事务所Fried, Frank, Harris, Shriver and Jacobson的外部律师。他是以色列一家清洁产品和原材料制造商Zohar Dalia公司主席。他目前在Beresheit General Partner Ltd.公司、Galam Ltd.公司、Cargal Ltd.公司、Plasto-sac Ltd.公司、Controp Ltd. 公司和 Aeronautics Ltd.公司担任职位。他在以色列特拉维夫大学（Tel Aviv University）获得工业工程学位、法学学士、法学硕士，并获得法学博士学位。依据我公司公司首次公开发行前生效的章程，根据Galam任命规则，他担任我们公司董事。
Imanuel Wasserman has served as a director of Enzymotec since October 2011. Dr. Wasserman is a co-founder of Beresheit General Partner Ltd., the general partner of Manof I funds, a NIS 2 billion Israeli fund, and has served as its managing partner since its inception in 2009. Previously, he was a co-founder and managing director of Magna Capital Ltd., an Israeli strategy and M&A consulting firm, from 2000 to 2009. In addition, Dr. Wasserman worked as a lawyer, from 1992 to 1994 and from 1997 to 1999 with Zellermayer Pelossof and Co., an Israeli law firm. From 1995 to 1996 he was a foreign lawyer at Fried, Frank, Harris, Shriver and Jacobson, a U.S. law firm. Dr. Wasserman is the chairman of Zohar Dalia, an Israeli manufacturer of cleaning products and raw materials. He currently serves as a director for the following companies: Beresheit General Partner Ltd., Galam Ltd., Cargal Ltd., Plasto-sac Ltd. TASE: PLST, Controp Ltd., Aeronautics Ltd. and Liberty Properties Ltd. Dr. Wasserman holds a bachelor’s degree in industrial engineering, an LLB, an LLM and a doctorate in law, all from Tel Aviv University. Dr. Wasserman was appointed as a director pursuant to Galam’s appointment rights under our articles of association in effect prior to our initial public offering. Mr. Wasserman was re-elected as director in 2015. - Imanuel Wasserman，自2011年担任Enzymotec董事。Wasserman博士是Beresheit General Partner Ltd.公司的联合创立者，是一家以色列网络信息服务20亿基金会（NIS 2 billion Israeli fund）Manof I funds的普通合伙人，并自该公司2009年起担任任事股东。他是三个由以色列政府最初建立的最大的Manof基金之一，通过提供债务、中间商及股权融资为以色列经济提供流动资产。以色列政府决心将5亿投资到NIS，由以色列的主导金融机构投资剩余的1.5亿。之前于2000年至2009年他是以色列战略和M&A咨询公司Magna Capital Ltd.的联合创立者和董事总经理。另外，他作为律师，于1992年至1994年至1997年至1999年就职于Zellermayer Pelossof and Co.，该公司是一家以色列律师事务所。1995年至1996年，他是美国一家律师事务所Fried, Frank, Harris, Shriver and Jacobson的外部律师。他是以色列一家清洁产品和原材料制造商Zohar Dalia公司主席。他目前在Beresheit General Partner Ltd.公司、Galam Ltd.公司、Cargal Ltd.公司、Plasto-sac Ltd.公司、Controp Ltd. 公司和 Aeronautics Ltd.公司担任职位。他在以色列特拉维夫大学（Tel Aviv University）获得工业工程学位、法学学士、法学硕士，并获得法学博士学位。依据我公司公司首次公开发行前生效的章程，根据Galam任命规则，他担任我们公司董事。
- Imanuel Wasserman has served as a director of Enzymotec since October 2011. Dr. Wasserman is a co-founder of Beresheit General Partner Ltd., the general partner of Manof I funds, a NIS 2 billion Israeli fund, and has served as its managing partner since its inception in 2009. Previously, he was a co-founder and managing director of Magna Capital Ltd., an Israeli strategy and M&A consulting firm, from 2000 to 2009. In addition, Dr. Wasserman worked as a lawyer, from 1992 to 1994 and from 1997 to 1999 with Zellermayer Pelossof and Co., an Israeli law firm. From 1995 to 1996 he was a foreign lawyer at Fried, Frank, Harris, Shriver and Jacobson, a U.S. law firm. Dr. Wasserman is the chairman of Zohar Dalia, an Israeli manufacturer of cleaning products and raw materials. He currently serves as a director for the following companies: Beresheit General Partner Ltd., Galam Ltd., Cargal Ltd., Plasto-sac Ltd. TASE: PLST, Controp Ltd., Aeronautics Ltd. and Liberty Properties Ltd. Dr. Wasserman holds a bachelor’s degree in industrial engineering, an LLB, an LLM and a doctorate in law, all from Tel Aviv University. Dr. Wasserman was appointed as a director pursuant to Galam’s appointment rights under our articles of association in effect prior to our initial public offering. Mr. Wasserman was re-elected as director in 2015.
- Michal Silverberg
-
Michal Silverberg，于2013年9月担任Enzymotec公司董事。自2007年，她就职于总部设在丹麦的跨国医疗保健公司Novo Nordisk Inc.公司，该公司股票在哥本哈根和纽约证券交易所（Copenhagen and New York Stock Exchanges）上市。自2010年起她担任生物药剂学新产品商业化及商业开发的资深总监。加入Novo Nordisk公司之前，她在生物技术公司投资部门多个职位工作，并担任以色列科技培养中心（Israel Technological Incubators）首席科学家。她在以色列海法大学（Haifa University, Israel）获得经济学和工商管理学士，并在以色列特拉维斯大学（Tel Aviv University, Israel）获得MBA，在纽约市哥伦比亚大学（Columbia University, New York）获得生物技术专业硕士学位。
Michal Silverberg has been a member of our board of directors since October 2017. Ms. Silverberg current serves as a Managing Director at the Novartis Venture Fund, where she has been employed since October 2017. Prior to joining Novartis Venture Fund, she was a Senior Partner at Takeda Ventures from September 2014 through September 2017 and, before that, worked at Novo Nordisk from March 2007 through April 2013 in roles of increasing responsibility including as Senior Director Business Development and New Product Commercialization, serving as a member of the BioPharm leadership team. Since 1998 Ms. Silverberg has held positions in various sectors of the life science industry including in the Office of the Chief Scientist of Israel The Incubator program, venture capital (Ofer Brothers Hi Tech) and global pharmaceutical and biotech companies, including various positions at Multi Gene Vascular Systems Ltd., an Israeli biotech company and at OSI Pharmaceuticals in a business development role. Ms. Silverberg served as a member of the board of directors of publicly traded company Enzymotec Ltd. from its initial public offering in September 2013 until the company was acquired in October 2017. Ms. Silverberg holds a B.A. in economics and business management from Haifa University, an M.B.A from Tel-Aviv University in Israel and an M.A. in biotechnology from Columbia University. Ms. Silverberg resigned from our board of directors effective June 18 2020. Ms. Silverberg’s resignation was not due to any disagreement with the Company or any matters relating to our operations, policies or practices. - Michal Silverberg，于2013年9月担任Enzymotec公司董事。自2007年，她就职于总部设在丹麦的跨国医疗保健公司Novo Nordisk Inc.公司，该公司股票在哥本哈根和纽约证券交易所（Copenhagen and New York Stock Exchanges）上市。自2010年起她担任生物药剂学新产品商业化及商业开发的资深总监。加入Novo Nordisk公司之前，她在生物技术公司投资部门多个职位工作，并担任以色列科技培养中心（Israel Technological Incubators）首席科学家。她在以色列海法大学（Haifa University, Israel）获得经济学和工商管理学士，并在以色列特拉维斯大学（Tel Aviv University, Israel）获得MBA，在纽约市哥伦比亚大学（Columbia University, New York）获得生物技术专业硕士学位。
- Michal Silverberg has been a member of our board of directors since October 2017. Ms. Silverberg current serves as a Managing Director at the Novartis Venture Fund, where she has been employed since October 2017. Prior to joining Novartis Venture Fund, she was a Senior Partner at Takeda Ventures from September 2014 through September 2017 and, before that, worked at Novo Nordisk from March 2007 through April 2013 in roles of increasing responsibility including as Senior Director Business Development and New Product Commercialization, serving as a member of the BioPharm leadership team. Since 1998 Ms. Silverberg has held positions in various sectors of the life science industry including in the Office of the Chief Scientist of Israel The Incubator program, venture capital (Ofer Brothers Hi Tech) and global pharmaceutical and biotech companies, including various positions at Multi Gene Vascular Systems Ltd., an Israeli biotech company and at OSI Pharmaceuticals in a business development role. Ms. Silverberg served as a member of the board of directors of publicly traded company Enzymotec Ltd. from its initial public offering in September 2013 until the company was acquired in October 2017. Ms. Silverberg holds a B.A. in economics and business management from Haifa University, an M.B.A from Tel-Aviv University in Israel and an M.A. in biotechnology from Columbia University. Ms. Silverberg resigned from our board of directors effective June 18 2020. Ms. Silverberg’s resignation was not due to any disagreement with the Company or any matters relating to our operations, policies or practices.
高管简历
中英对照 | 中文 | 英文- Robert Crim
Robert Crim自2014年8月起担任Vaya Pharma USA的总裁和首席执行官。他在全球临床营养学和医学食品领域有着超过15年的经验。在加入Vaya Pharma（2010-2014年）之前，他是专注医疗营养和医疗保健客户的独立顾问。2004-2010年他在Danone/Numico担任许多岗位，承担着日益重要的责任，包括SHS business总经理与北美和全球商务拓展区域副总裁，他也在医学营养部门执行委员会工作。在那之前，他在Abbott担任各种职位，包括消费营养品副总裁，负责Ensure and Glucerna 的业务。他也在Johnson & Johnson和Procter 和Gamble工作。他取得密歇根大学（University of Michigan）工商管理硕士学位和哈佛大学（Harvard University）学士学位。
Robert Crim has served as President and CEO of Vaya Pharma USA since August 2014. Mr. Crim has over 15 years of experience in the global clinical nutrition and medical foods area. Prior to joining Vaya Pharma, from 2010 to 2014 Mr. Crim was an independent consultant focusing on medical nutrition and healthcare clients. From 2004 to 2010 he held positions of increasing responsibility at Danone/Numico, including General Manager of the SHS business and Regional Vice President - North America and Global Business Development as well as serving on the Executive Committee of the Medical Nutrition Division. Prior to that, Mr. Crim held positions at Abbott, including Vice President - Consumer Nutritionals where he was responsible for the Ensure and Glucerna businesses. Mr. Crim has also held positions at Johnson & Johnson and Procter and Gamble. He received his M.B.A. from University of Michigan and his B.A. from Harvard University.- Robert Crim自2014年8月起担任Vaya Pharma USA的总裁和首席执行官。他在全球临床营养学和医学食品领域有着超过15年的经验。在加入Vaya Pharma（2010-2014年）之前，他是专注医疗营养和医疗保健客户的独立顾问。2004-2010年他在Danone/Numico担任许多岗位，承担着日益重要的责任，包括SHS business总经理与北美和全球商务拓展区域副总裁，他也在医学营养部门执行委员会工作。在那之前，他在Abbott担任各种职位，包括消费营养品副总裁，负责Ensure and Glucerna 的业务。他也在Johnson & Johnson和Procter 和Gamble工作。他取得密歇根大学（University of Michigan）工商管理硕士学位和哈佛大学（Harvard University）学士学位。
- Robert Crim has served as President and CEO of Vaya Pharma USA since August 2014. Mr. Crim has over 15 years of experience in the global clinical nutrition and medical foods area. Prior to joining Vaya Pharma, from 2010 to 2014 Mr. Crim was an independent consultant focusing on medical nutrition and healthcare clients. From 2004 to 2010 he held positions of increasing responsibility at Danone/Numico, including General Manager of the SHS business and Regional Vice President - North America and Global Business Development as well as serving on the Executive Committee of the Medical Nutrition Division. Prior to that, Mr. Crim held positions at Abbott, including Vice President - Consumer Nutritionals where he was responsible for the Ensure and Glucerna businesses. Mr. Crim has also held positions at Johnson & Johnson and Procter and Gamble. He received his M.B.A. from University of Michigan and his B.A. from Harvard University.
- Itay Dromi
Itay Dromi 自2014年7月起担任公司人力资源的副总裁。Dromi先生拥有20多年的人力资源和组织管理的全球经验。加盟Enzymotec之前，2010年至2014年Dromi先生在Teva Pharmaceutical, Ltd担任多个人力资源职位，其中包括担任人力资源TGO亚洲地区的副总裁；担任化工部人力资源的副总裁。Dromi先生在Ultrashape和Delta Galil Industries曾担任人力资源职位。Dromi先生获得了Bar Ilan University工商管理硕士学位和University of Haifa的公共管理硕士学位。
Itay Dromi has served as our Vice President - Human Resources since July 2014. Mr. Dromi has over 20 years of global experience in human resources and organizational management. Prior to joining Enzymotec, Mr. Dromi served from 2010 to 2014 in multiple senior human resources positions at Teva Pharmaceutical Industries Ltd., including as Vice President - Human Resources TGO Asia Region and as Vice President - Human Resources of the Chemical Division. Mr. Dromi previously held human resources positions at Ultrashape and Delta Galil Industries. Mr. Dromi received his M.B.A from Bar Ilan University and an M.A. in Public Administration from the University of Haifa, Israel.- Itay Dromi 自2014年7月起担任公司人力资源的副总裁。Dromi先生拥有20多年的人力资源和组织管理的全球经验。加盟Enzymotec之前，2010年至2014年Dromi先生在Teva Pharmaceutical, Ltd担任多个人力资源职位，其中包括担任人力资源TGO亚洲地区的副总裁；担任化工部人力资源的副总裁。Dromi先生在Ultrashape和Delta Galil Industries曾担任人力资源职位。Dromi先生获得了Bar Ilan University工商管理硕士学位和University of Haifa的公共管理硕士学位。
- Itay Dromi has served as our Vice President - Human Resources since July 2014. Mr. Dromi has over 20 years of global experience in human resources and organizational management. Prior to joining Enzymotec, Mr. Dromi served from 2010 to 2014 in multiple senior human resources positions at Teva Pharmaceutical Industries Ltd., including as Vice President - Human Resources TGO Asia Region and as Vice President - Human Resources of the Chemical Division. Mr. Dromi previously held human resources positions at Ultrashape and Delta Galil Industries. Mr. Dromi received his M.B.A from Bar Ilan University and an M.A. in Public Administration from the University of Haifa, Israel.
- Yael Richter
Yael Richter 自2015年10月起担任研发的副总裁。此前，她曾担任我们的研发主任；自2006年5月加入Enzymotec起，担任AYA Pharma的研发团队的负责人。她还负责建设VAYA Pharma的医疗事务组，支持所有的科学宣传和教育活动。她获得 Hebrew University化学的学士学位和以色列Bar-Ilan University化学的博士学位，在那里她专门从事药物化学。
Yael Richter has served as our Vice President - Research and Development since October 2015. Previously, she served as our Director of Research and Development and as the head of VAYA Pharma’s research and development team since joining Enzymotec in May 2006. She was also responsible for building VAYA Pharma’s medical affairs team, supporting all the scientific communication and education activities. She holds a bachelor’s degree in Chemistry from the Hebrew University and a PhD in chemistry from Bar-Ilan University, Israel, where she specialized in medicinal chemistry.- Yael Richter 自2015年10月起担任研发的副总裁。此前，她曾担任我们的研发主任；自2006年5月加入Enzymotec起，担任AYA Pharma的研发团队的负责人。她还负责建设VAYA Pharma的医疗事务组，支持所有的科学宣传和教育活动。她获得 Hebrew University化学的学士学位和以色列Bar-Ilan University化学的博士学位，在那里她专门从事药物化学。
- Yael Richter has served as our Vice President - Research and Development since October 2015. Previously, she served as our Director of Research and Development and as the head of VAYA Pharma’s research and development team since joining Enzymotec in May 2006. She was also responsible for building VAYA Pharma’s medical affairs team, supporting all the scientific communication and education activities. She holds a bachelor’s degree in Chemistry from the Hebrew University and a PhD in chemistry from Bar-Ilan University, Israel, where she specialized in medicinal chemistry.
- Avner Avissara
Avner Avissara自2016年7月起担任我们的Vice President营养部。在成为我们的Vice President-Nutrition Dividion之前，他曾于2014年5月至2015年12月担任亚太地区和中国地区总监，并于2015年1月至2016年12月担任Advanced Lipides的首席执行官，同时领导我们的婴儿营养业务。Avissara先生在制药行业拥有超过20年的经验。从1993年到2010年，他管理以色列的Teva Clinical Nutrition业务，后来帮助建立Teva Pharmaceutical International公司在中东欧、巴尔干、非洲和其他地区的业务。在Teva Pharmaceutical Daughter Companies的区域总监和总经理以及董事会成员的职位上，Avissara先生专门从事新业务的建立，并通过各种商业模式领导组织的增长。Avissara先生拥有理学学士学位。耶路撒冷希伯来大学（Hebrew University of Jerusalem）生物化学和人类营养学学士学位和爱丁堡大学（Edinburgh University）工商管理硕士学位。
Avner Avissara has served as our Vice President-Nutrition Division since July 2016. Prior to becoming our Vice President - Nutrition Dividion, he served as Regional Director of Asia Pacific and China from May 2014 to December 2015 and as the CEO of Advanced Lipids from January 2015 to December 2016 while also leading our infant nutrition business. Mr. Avissara has over 20 years of experience in the pharmaceutical industry. Between 1993 and 2010 he managed the Teva Clinical Nutrition business in Israel and later helped to establish Teva Pharmaceutical International’s business in Central Eastern Europe, the Balkans, Africa and other regions. In the positions of Regional Director and General Manager of the territories as well as member of the board of Director of Teva Pharmaceutical daughter companies, Mr. Avissara specialized in the establishment of new businesses and led the growth of the organizations through various business models. Mr. Avissara Holds a BSc. in Biochemistry and Human Nutrition from the Hebrew University of Jerusalem and an MBA from Edinburgh University.- Avner Avissara自2016年7月起担任我们的Vice President营养部。在成为我们的Vice President-Nutrition Dividion之前，他曾于2014年5月至2015年12月担任亚太地区和中国地区总监，并于2015年1月至2016年12月担任Advanced Lipides的首席执行官，同时领导我们的婴儿营养业务。Avissara先生在制药行业拥有超过20年的经验。从1993年到2010年，他管理以色列的Teva Clinical Nutrition业务，后来帮助建立Teva Pharmaceutical International公司在中东欧、巴尔干、非洲和其他地区的业务。在Teva Pharmaceutical Daughter Companies的区域总监和总经理以及董事会成员的职位上，Avissara先生专门从事新业务的建立，并通过各种商业模式领导组织的增长。Avissara先生拥有理学学士学位。耶路撒冷希伯来大学（Hebrew University of Jerusalem）生物化学和人类营养学学士学位和爱丁堡大学（Edinburgh University）工商管理硕士学位。
- Avner Avissara has served as our Vice President-Nutrition Division since July 2016. Prior to becoming our Vice President - Nutrition Dividion, he served as Regional Director of Asia Pacific and China from May 2014 to December 2015 and as the CEO of Advanced Lipids from January 2015 to December 2016 while also leading our infant nutrition business. Mr. Avissara has over 20 years of experience in the pharmaceutical industry. Between 1993 and 2010 he managed the Teva Clinical Nutrition business in Israel and later helped to establish Teva Pharmaceutical International’s business in Central Eastern Europe, the Balkans, Africa and other regions. In the positions of Regional Director and General Manager of the territories as well as member of the board of Director of Teva Pharmaceutical daughter companies, Mr. Avissara specialized in the establishment of new businesses and led the growth of the organizations through various business models. Mr. Avissara Holds a BSc. in Biochemistry and Human Nutrition from the Hebrew University of Jerusalem and an MBA from Edinburgh University.
- Efrat Manoff
Efrat Manoff自2016年3月起担任我们的运营副总裁。2012年至2016年，她曾担任BAI业务部门的产品经理。Efrat的职业生涯始于担任Perrigo Pharmaceutical Plant in Israel的研发和试点工艺部的化学工程师。Manoff女士持有以色列Beer Sheva的Ben Gurion University的化学工程理学士学位以及该大学的环境工程理学硕士学位。
Efrat Manoff has served as our Vice- President - Operations since March 2016. Between 2012 and 2016 she was the BAI business unit's product manager. Efrat started her professional career as a chemical engineer in the R&D and Pilot process department of Perrigo Pharmaceutical plant in Israel. Ms. Manoff is holding a Bachelor of Science in Chemical Engineering from Ben Gurion University in Beer Sheva, Israel and Master of Science in Environmental Engineering from this university.- Efrat Manoff自2016年3月起担任我们的运营副总裁。2012年至2016年，她曾担任BAI业务部门的产品经理。Efrat的职业生涯始于担任Perrigo Pharmaceutical Plant in Israel的研发和试点工艺部的化学工程师。Manoff女士持有以色列Beer Sheva的Ben Gurion University的化学工程理学士学位以及该大学的环境工程理学硕士学位。
- Efrat Manoff has served as our Vice- President - Operations since March 2016. Between 2012 and 2016 she was the BAI business unit's product manager. Efrat started her professional career as a chemical engineer in the R&D and Pilot process department of Perrigo Pharmaceutical plant in Israel. Ms. Manoff is holding a Bachelor of Science in Chemical Engineering from Ben Gurion University in Beer Sheva, Israel and Master of Science in Environmental Engineering from this university.
- Ariel Katz
Ariel Katz，于2000年加入Enzymotec Ltd.公司并担任总裁和CEO。他自2012年1月担任我公司VAYA Pharma分部领导。加入Enzymotec之前，他在14年时间里担任Israel Chemicals Ltd.公司Dead Sea Bromin集团多种职位，包括研究与开发、工厂管理、营销和商业开发等。他在位于以色列本古里安大学（Ben-Gurion University of the Negev, Beer Sheva, Israel）获得化学学士学位、经济管理硕士学位，在英国埃克赛特大学（Exeter University, UK）获得人工智能工程学博士。他于2003年至2010年是以色列海法市以色列理工大学（Technion - Israel Institute of Technology, Haifa, Israel）生物技术部科所教授。
Ariel Katz has served as our President and Chief Executive Officer since joining us in 2000. He has also served as the head of our VAYA Pharma segment from January 2012 to August 2014. Prior to joining Enzymotec, Dr. Katz held various positions with the Dead Sea Bromine Group of Israel Chemicals Ltd. over a period of 14 years, including senior positions in research and development, plant management, marketing and business development. Dr. Katz holds a bachelor’s degree in chemistry and a master’s degree in economic management both from Ben-Gurion University of the Negev, Beer Sheva, Israel, and a PhD in engineering in the field of artificial intelligence from Exeter University, UK. Dr. Katz was a guest lecturer in the Biotechnology Department of the Technion - Israel Institute of Technology, Israel from 2003 to 2010. Dr. Katz will step down as President and Chief Executive Officer effective as of April 18 2017 2017 but will remain with the Company through May to ensure a smooth transition for his successor, Mr. Erez Israeli, whose appointment will become effective as of April 18 2017.- Ariel Katz，于2000年加入Enzymotec Ltd.公司并担任总裁和CEO。他自2012年1月担任我公司VAYA Pharma分部领导。加入Enzymotec之前，他在14年时间里担任Israel Chemicals Ltd.公司Dead Sea Bromin集团多种职位，包括研究与开发、工厂管理、营销和商业开发等。他在位于以色列本古里安大学（Ben-Gurion University of the Negev, Beer Sheva, Israel）获得化学学士学位、经济管理硕士学位，在英国埃克赛特大学（Exeter University, UK）获得人工智能工程学博士。他于2003年至2010年是以色列海法市以色列理工大学（Technion - Israel Institute of Technology, Haifa, Israel）生物技术部科所教授。
- Ariel Katz has served as our President and Chief Executive Officer since joining us in 2000. He has also served as the head of our VAYA Pharma segment from January 2012 to August 2014. Prior to joining Enzymotec, Dr. Katz held various positions with the Dead Sea Bromine Group of Israel Chemicals Ltd. over a period of 14 years, including senior positions in research and development, plant management, marketing and business development. Dr. Katz holds a bachelor’s degree in chemistry and a master’s degree in economic management both from Ben-Gurion University of the Negev, Beer Sheva, Israel, and a PhD in engineering in the field of artificial intelligence from Exeter University, UK. Dr. Katz was a guest lecturer in the Biotechnology Department of the Technion - Israel Institute of Technology, Israel from 2003 to 2010. Dr. Katz will step down as President and Chief Executive Officer effective as of April 18 2017 2017 but will remain with the Company through May to ensure a smooth transition for his successor, Mr. Erez Israeli, whose appointment will become effective as of April 18 2017.
- Oren Bryan
Oren Bryan自2008年6月担任Enzymotec Ltd.公司副总裁和首席财务官。在此之前，他于2006年至2008年担任MIND C.T.I. Ltd.公司首席财务官，该公司为全球提供实时的，以产品为基础的调解、计费和客户服务解决方案，实现语音，数据，视频和内容服务的全球供应。他于2005年至2006年担任MIND C.T.I. Ltd.公司财务总监。在MIND C.T.I. Ltd.公司工作之前，他于2001年至2005年担任Dor Chemicals Ltd.公司财务总监，并在2000年至2001年担任一家私人软件公司财务总监。1997年至2000年，他是Ernst & Young Global 公司的成员Kost, Forer, Gabbay and Kasierer公司的会计。他是一名注册会计师，并在以色列海法大学（Haifa University, Israel）获得经济学和会计学学士学位。
Oren Bryan has served as our Vice President and Chief Financial Officer since June 2008. Prior to joining Enzymotec, he served as Chief Financial Officer of MIND C.T.I. Ltd., a global provider of real-time, product-based mediation, billing and customer care solutions for voice, data, video and content service from 2006 to 2008 and Controller of MIND C.T.I. Ltd. from 2005 to 2006. Before working at MIND C.T.I. Ltd., Mr. Bryan served as Controller of both Dor Chemicals Ltd. from 2001 to 2005 and a private software company from 2000 to 2001. Between 1997 and 2000 he was an accountant with Kost, Forer, Gabbay and Kasierer, a member of Ernst & Young Global. Mr. Bryan is a certified public accountant and holds a B.A. in economics and accounting from University of Haifa, Israel.- Oren Bryan自2008年6月担任Enzymotec Ltd.公司副总裁和首席财务官。在此之前，他于2006年至2008年担任MIND C.T.I. Ltd.公司首席财务官，该公司为全球提供实时的，以产品为基础的调解、计费和客户服务解决方案，实现语音，数据，视频和内容服务的全球供应。他于2005年至2006年担任MIND C.T.I. Ltd.公司财务总监。在MIND C.T.I. Ltd.公司工作之前，他于2001年至2005年担任Dor Chemicals Ltd.公司财务总监，并在2000年至2001年担任一家私人软件公司财务总监。1997年至2000年，他是Ernst & Young Global 公司的成员Kost, Forer, Gabbay and Kasierer公司的会计。他是一名注册会计师，并在以色列海法大学（Haifa University, Israel）获得经济学和会计学学士学位。
- Oren Bryan has served as our Vice President and Chief Financial Officer since June 2008. Prior to joining Enzymotec, he served as Chief Financial Officer of MIND C.T.I. Ltd., a global provider of real-time, product-based mediation, billing and customer care solutions for voice, data, video and content service from 2006 to 2008 and Controller of MIND C.T.I. Ltd. from 2005 to 2006. Before working at MIND C.T.I. Ltd., Mr. Bryan served as Controller of both Dor Chemicals Ltd. from 2001 to 2005 and a private software company from 2000 to 2001. Between 1997 and 2000 he was an accountant with Kost, Forer, Gabbay and Kasierer, a member of Ernst & Young Global. Mr. Bryan is a certified public accountant and holds a B.A. in economics and accounting from University of Haifa, Israel.
- Gai Ben Dror
Gai Ben Dror，担任Enzymotec Ltd.公司工艺开发副总裁，之前于2001年12月加入Enzymotec公司并担任工艺开发主管。在担任工艺开发主管期间，他负责我公司所有产品的开发和商业化，并负责组建Enzymotec Ltd.公司技术和分析团队。加入Enzymotec Ltd.公司之前，他于1996年至2000年担任Dead Sea Bromine Group of Israel Chemicals Ltd.公司车间和试验工程师。在此之前，他任职于计算机硬件开发公司Sense-IT Ltd.的研究团队，并担任水处理工程公司Chimtec Ltd.的项目经理。他在以色列本古里安大学（Ben-Gurion University of the Negev, Beer Sheva, Israel）获得化学工程学士学位和MBA学位。
Gai Ben Dror has served as our Vice President - Process Development and previously as our Director of Process Development since joining Enzymotec in December 2001. As Director of Process Development, he was responsible for the development and commercialization of all of our products and for the building of our technological and analytical teams. Prior to joining us, Mr. Ben-Dror was a plant and pilot engineer in the Dead Sea Bromine Group of Israel Chemicals Ltd. from 1996 to 2000. Prior to that he worked as a research team leader at Sense-IT Ltd., a hardware development company, and as a project manager at Chimtec Ltd., a water treatment engineering company. He holds a bachelor’s degree in chemical engineering and an M.B.A. from Ben-Gurion University of the Negev, Beer Sheva, Israel.- Gai Ben Dror，担任Enzymotec Ltd.公司工艺开发副总裁，之前于2001年12月加入Enzymotec公司并担任工艺开发主管。在担任工艺开发主管期间，他负责我公司所有产品的开发和商业化，并负责组建Enzymotec Ltd.公司技术和分析团队。加入Enzymotec Ltd.公司之前，他于1996年至2000年担任Dead Sea Bromine Group of Israel Chemicals Ltd.公司车间和试验工程师。在此之前，他任职于计算机硬件开发公司Sense-IT Ltd.的研究团队，并担任水处理工程公司Chimtec Ltd.的项目经理。他在以色列本古里安大学（Ben-Gurion University of the Negev, Beer Sheva, Israel）获得化学工程学士学位和MBA学位。
- Gai Ben Dror has served as our Vice President - Process Development and previously as our Director of Process Development since joining Enzymotec in December 2001. As Director of Process Development, he was responsible for the development and commercialization of all of our products and for the building of our technological and analytical teams. Prior to joining us, Mr. Ben-Dror was a plant and pilot engineer in the Dead Sea Bromine Group of Israel Chemicals Ltd. from 1996 to 2000. Prior to that he worked as a research team leader at Sense-IT Ltd., a hardware development company, and as a project manager at Chimtec Ltd., a water treatment engineering company. He holds a bachelor’s degree in chemical engineering and an M.B.A. from Ben-Gurion University of the Negev, Beer Sheva, Israel.